Artax Biopharma is a clinical stage biotechnology company that develops novel treatments for autoimmune diseases.
The lead product, AX-158, is a first-in-class, oral small molecule that inhibits Nck’s binding to the T cell receptor (TCR). Through this novel mechanism, it selectively modulates Nck’s amplification of the TCR signal, resulting in a lower T Cell activation and lower T Cell response.
Location: Cambridge, USA
Sound contact: Casper Breum (Board Director) and Ester Sklarsky (Board Observer)
Read an interview with Joseph Lobacki, CEO: A patient-centric mission for life-changing autoimmune treatments
Related news
- Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158.
- Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study
- Artax Announces Executive Team Changes, Expansion as Company Heads into Pivotal 2024 Year
- Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases
- A patient-centric mission for life-changing autoimmune treatments
- Artax Biopharma Expands Company’s Scientific Advisory Board and Welcomes James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D., Both Experts in T-Cell-Mediated Diseases
- Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
